Exagen (NASDAQ:XGN) Stock Price Up 1.4% - Time to Buy?

Exagen Inc. (NASDAQ:XGN - Get Free Report) traded up 1.4% on Tuesday . The stock traded as high as $5.30 and last traded at $5.02. 65,825 shares traded hands during trading, an increase of 18% from the average session volume of 55,687 shares. The stock had previously closed at $4.95.

Analyst Upgrades and Downgrades

Separately, William Blair reissued an "outperform" rating on shares of Exagen in a report on Wednesday, November 13th.

Exagen Stock Up 1.4 %

The business's fifty day moving average price is $3.71 and its 200 day moving average price is $2.93. The firm has a market capitalization of $88.54 million, a price-to-earnings ratio of -5.34 and a beta of 1.49. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54.

Exagen (NASDAQ:XGN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02. The company had revenue of $12.51 million during the quarter, compared to analysts' expectations of $13.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same period last year, the firm earned ($0.31) EPS. On average, equities analysts expect that Exagen Inc. will post -0.87 EPS for the current year.

Insider Buying and Selling at Exagen

In related news, major shareholder Nmsic Co-Investment Fund, L.P. sold 200,000 shares of the business's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $3.30, for a total value of $660,000.00. Following the completion of the transaction, the insider now owns 2,108,958 shares of the company's stock, valued at approximately $6,959,561.40. The trade was a 8.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John Aballi acquired 24,305 shares of the stock in a transaction dated Thursday, November 14th. The stock was acquired at an average cost of $2.81 per share, with a total value of $68,297.05. Following the transaction, the chief executive officer now owns 689,799 shares of the company's stock, valued at approximately $1,938,335.19. This trade represents a 3.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 26.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC increased its position in shares of Exagen by 93.3% in the 2nd quarter. Renaissance Technologies LLC now owns 94,234 shares of the company's stock worth $172,000 after purchasing an additional 45,476 shares during the last quarter. Creative Planning acquired a new position in Exagen in the third quarter worth about $110,000. Verus Capital Partners LLC bought a new stake in Exagen in the third quarter valued at about $39,000. Palumbo Wealth Management LLC raised its stake in Exagen by 14.5% during the third quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company's stock valued at $236,000 after buying an additional 9,695 shares in the last quarter. Finally, Stonepine Capital Management LLC lifted its holdings in Exagen by 49.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company's stock worth $1,651,000 after buying an additional 175,701 shares during the last quarter. Institutional investors and hedge funds own 75.25% of the company's stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).